Corcept Insider Sells Shares Following FDA Approval and $1.05 Billion Outlook
William Guyer, chief development officer at Corcept Therapeutics (NASDAQ:CORT), sold 20,000 shares worth approximately $1.9 million on July 7, 2026, as reported in an SEC Form 4 filing. The transaction was executed under a pre-scheduled Rule 10b5-1 trading plan and reduced his direct common stock holdings to 3,985 shares post-sale.
Tickers: $CORT